Kyowa Kirin expects top-line ProStrakan benefits this year
This article was originally published in Scrip
Executive Summary
Kyowa Hakko Kirin expects its new acquisition ProStrakan to add ¥7.4 billion ($94.8 million) to its net pharma sales this year, although amortisation costs associated with the now completed £292 million deal will dampen operating profit.